Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Allergy Clin Immunol ; 146(4): 863-874, 2020 10.
Article in English | MEDLINE | ID: mdl-32659313

ABSTRACT

BACKGROUND: The PEPITES (Peanut EPIT Efficacy and Safety) trial, a 12-month randomized controlled study of children with peanut allergy and 4 to 11 years old, previously reported the safety and efficacy of epicutaneous immunotherapy (EPIT) for peanut allergy (250 µg, daily epicutaneous peanut protein; DBV712 250 µg). OBJECTIVE: We sought to assess interim safety and efficacy of an additional 2 years of EPIT from the ongoing (5-year treatment) PEOPLE (PEPITES Open-Label Extension) study. METHODS: Subjects who completed PEPITES were offered enrollment in PEOPLE. Following an additional 2 years of daily DBV712 250 µg, subjects who had received DBV712 250 µg in PEPITES underwent month-36 double-blind, placebo-controlled food challenge with an optional month-38 sustained unresponsiveness assessment. RESULTS: Of 213 eligible subjects who had received DBV712 250 µg in PEPITES, 198 (93%) entered PEOPLE, of whom 141 (71%) had assessable double-blind, placebo-controlled food challenge at month 36. At month 36, 51.8% of subjects (73 of 141) reached an eliciting dose of ≥1000 mg, compared with 40.4% (57 of 141) at month 12; 75.9% (107 of 141) demonstrated increased eliciting dose compared with baseline; and 13.5% (19 of 141) tolerated the full double-blind, placebo-controlled food challenge of 5444 mg. Median cumulative reactive dose increased from 144 to 944 mg. Eighteen subjects underwent an optional sustained unresponsiveness assessment; 14 of those (77.8%) maintained an eliciting dose of ≥1000 mg at month 38. Local patch-site skin reactions were common but decreased over time. There was no treatment-related epinephrine use in years 2 or 3. Compliance was high (96.9%), and withdrawals due to treatment-related adverse events were low (1%). CONCLUSIONS: These results demonstrate that daily EPIT treatment for peanut allergy beyond 1 year leads to continued response from a well-tolerated, simple-to-use regimen.


Subject(s)
Allergens/immunology , Desensitization, Immunologic , Peanut Hypersensitivity/immunology , Peanut Hypersensitivity/therapy , Administration, Cutaneous , Adolescent , Allergens/administration & dosage , Biomarkers , Child , Child, Preschool , Desensitization, Immunologic/adverse effects , Desensitization, Immunologic/methods , Female , Follow-Up Studies , Humans , Immunoglobulin E/immunology , Male , Treatment Outcome
2.
J Clin Med ; 12(11)2023 Jun 01.
Article in English | MEDLINE | ID: mdl-37298008

ABSTRACT

BACKGROUND: Many treatments for actinic keratosis (AK) have been proven efficient in clinical trials. However, patients with AK may still experience unsatisfactory therapeutic outcomes in clinical practice. OBJECTIVES: To investigate patient adherence to self-applied topical interventions for AK and to explore factors associated with adherence in a real-world setting. METHODS: A cross-sectional study was conducted. Patients presenting with AK were asked to complete a self-administered questionnaire about their last topical AK treatment. RESULTS: A total of 113 patients participated with a median age of 78.5 years (range 58-94). Fifty-four patients (47.8%) received topical diclofenac, ten (8.8%) imiquimod, nine (8%) 5-fluorouracil, nine (8%) 5-fluorouracil plus salicylic acid, and eight (7.1%) photodynamic therapy. The non-adherence rate was 46.9% (n = 53), and only 30.9% (n = 35) used the topical treatments according to the summary of product characteristics (SmPC). These subgroups were compared. Patients of the non-compliant group were significantly less informed about the application time of the specific topical intervention (p = 0.002) and adjusted the timeframe (p < 0.001) and application frequency of the therapy (p = 0.02) independently of their physician. Conversely, patients reporting a sufficient pre-treatment consultation (p = 0.019) generally complied with the SmPC compliance application. CONCLUSIONS: A thorough pre-treatment consultation can help to increase treatment adherence and ensure lesion clearance.

5.
J Dtsch Dermatol Ges ; 6(9): 747-50, 2008 Sep.
Article in English, German | MEDLINE | ID: mdl-18266862

ABSTRACT

Lepidopterism by contact with oak processionary caterpillars is becoming more frequent in Germany and is often described in the lay press. The hairs of the adolescent caterpillars cause localized and generalized mechanic-irritative, toxic and allergic skin reactions. We describe the oak processionary caterpillar dermatitis in a married couple caused by indirect contact via their dog's saliva, after the dog had oral contact with an abandoned caterpillar nest in winter and became ill. Accordingly, the recommendation for prophylaxis by avoiding contact with oak processionary caterpillars has to be extended beyond the direct contact with caterpillars in summer.


Subject(s)
Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/immunology , Moths/immunology , Pruritus/diagnosis , Pruritus/immunology , Adult , Animals , Female , Humans , Male , Seasons
6.
Cell Metab ; 21(3): 493-501, 2015 Mar 03.
Article in English | MEDLINE | ID: mdl-25738463

ABSTRACT

Immune cells regulate a hypertonic microenvironment in the skin; however, the biological advantage of increased skin Na(+) concentrations is unknown. We found that Na(+) accumulated at the site of bacterial skin infections in humans and in mice. We used the protozoan parasite Leishmania major as a model of skin-prone macrophage infection to test the hypothesis that skin-Na(+) storage facilitates antimicrobial host defense. Activation of macrophages in the presence of high NaCl concentrations modified epigenetic markers and enhanced p38 mitogen-activated protein kinase (p38/MAPK)-dependent nuclear factor of activated T cells 5 (NFAT5) activation. This high-salt response resulted in elevated type-2 nitric oxide synthase (Nos2)-dependent NO production and improved Leishmania major control. Finally, we found that increasing Na(+) content in the skin by a high-salt diet boosted activation of macrophages in a Nfat5-dependent manner and promoted cutaneous antimicrobial defense. We suggest that the hypertonic microenvironment could serve as a barrier to infection.


Subject(s)
Anti-Infective Agents/pharmacology , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/metabolism , Macrophages/metabolism , Skin/metabolism , Sodium/metabolism , Animals , Enzyme Activation/physiology , Humans , Leishmania major/drug effects , Macrophages/drug effects , Mice , NFATC Transcription Factors/metabolism , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Skin/drug effects , p38 Mitogen-Activated Protein Kinases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL